Abigail Jenkins is an award-winning, battle-tested pharmaceutical executive with more than 25 years of experience in transforming companies and bringing novel therapies to market. As a former President, CEO, and Board Member at a commercial-stage biotech, she led a drug approval in 2023 in the oncology/cell therapy space, and has a proven record in creating value, raising $265M+ in equity capital, securing over $500M in non-dilutive funding, and closing deals including a $270M acquisition that contributed $50M in first-year revenue.

Her expertise spans commercial launches and re-launches across therapeutic areas such as infectious disease, vaccines, respiratory, cardiovascular, urology, pain, CNS, and oncology, serving both large pharma and biotech, in primary care and rare disease settings, and in domestic and international markets. Known as a catalyst leader, she guides organizations with clarity, connection, and courage.